Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
$25.61
+0.5%
$24.77
$22.48
$71.71
$1.51B2.86866,514 shs760,748 shs
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$83.83
+0.4%
$80.81
$73.11
$126.89
$5.78B0.12997,948 shs814,865 shs
Nuvalent, Inc. stock logo
NUVL
Nuvalent
$82.07
+0.7%
$75.73
$55.54
$113.51
$5.85B1.31507,985 shs410,391 shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$16.10
-4.8%
$16.73
$13.61
$30.36
$5.73BN/A29,143 shs28,191 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
+0.47%+4.36%-2.40%-11.08%-38.36%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
+0.41%+5.83%+4.24%-17.81%-21.05%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
+0.70%+2.12%+3.28%+23.80%+10.13%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
-4.85%-0.15%-6.77%-3.30%+1,609,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
1.6261 of 5 stars
3.51.00.00.00.62.50.0
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
4.4923 of 5 stars
3.51.00.04.22.42.51.9
Nuvalent, Inc. stock logo
NUVL
Nuvalent
3.8014 of 5 stars
4.63.00.00.02.73.30.0
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
3.09
Buy$95.25271.93% Upside
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
3.00
Buy$130.5055.67% Upside
Nuvalent, Inc. stock logo
NUVL
Nuvalent
3.17
Buy$119.6045.73% Upside
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
3.00
Buy$22.3338.72% Upside

Current Analyst Ratings Breakdown

Latest JANX, NUVL, LNTH, and TLX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
7/3/2025
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$23.00
6/30/2025
Nuvalent, Inc. stock logo
NUVL
Nuvalent
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/25/2025
Nuvalent, Inc. stock logo
NUVL
Nuvalent
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$105.00 ➝ $112.00
6/24/2025
Nuvalent, Inc. stock logo
NUVL
Nuvalent
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$115.00
6/24/2025
Nuvalent, Inc. stock logo
NUVL
Nuvalent
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$125.00 ➝ $140.00
6/24/2025
Nuvalent, Inc. stock logo
NUVL
Nuvalent
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$110.00 ➝ $130.00
6/23/2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$122.00 ➝ $109.00
6/12/2025
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$22.00
6/5/2025
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$22.00
5/8/2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$127.00 ➝ $117.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
$9.34M162.33N/AN/A$19.49 per share1.31
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.53B3.78$7.12 per share11.77$15.65 per share5.36
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/AN/AN/AN/A$14.99 per shareN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$516.72M10.54$0.11 per share148.17$1.12 per share14.38
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-$68.99M-$1.36N/AN/AN/AN/A-9.29%-8.89%8/6/2025 (Estimated)
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$312.44M$3.5223.8213.29N/A16.55%36.99%20.55%7/30/2025 (Estimated)
Nuvalent, Inc. stock logo
NUVL
Nuvalent
-$260.76M-$4.39N/AN/AN/AN/A-31.35%-29.27%8/14/2025 (Estimated)
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$32.93MN/A0.0033.54N/AN/AN/AN/AN/A

Latest JANX, NUVL, LNTH, and TLX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-$0.50N/AN/AN/A$0.30 millionN/A
7/30/2025Q2 2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.65N/AN/AN/A$389.69 millionN/A
5/8/2025Q1 2025
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-$0.43-$0.38+$0.05-$0.38$0.59 millionN/A
5/8/2025Q1 2025
Nuvalent, Inc. stock logo
NUVL
Nuvalent
-$1.14-$1.18-$0.04-$1.18N/AN/A
5/7/2025Q1 2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.64$1.53-$0.11$1.02$377.37 million$372.76 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
N/AN/AN/AN/AN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
N/AN/AN/AN/AN/A
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/AN/AN/AN/AN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
N/A
58.47
58.47
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
0.49
5.74
5.46
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/A
14.48
14.48
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
0.99
2.78
2.66

Institutional Ownership

CompanyInstitutional Ownership
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
75.39%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
99.06%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
97.26%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
8.10%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
1.50%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
10.20%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
3059.18 million54.38 millionOptionable
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
70069.19 million68.15 millionOptionable
Nuvalent, Inc. stock logo
NUVL
Nuvalent
4071.81 million64.48 millionOptionable
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A338.38 millionN/AN/A

Recent News About These Companies

Gozellix Receives Permanent HCPCS Code
Telix shares jump 7% on big US news

New MarketBeat Followers Over Time

Media Sentiment Over Time

Janux Therapeutics stock logo

Janux Therapeutics NASDAQ:JANX

$25.61 +0.12 (+0.47%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$25.27 -0.34 (-1.33%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Lantheus stock logo

Lantheus NASDAQ:LNTH

$83.83 +0.34 (+0.41%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$84.50 +0.67 (+0.80%)
As of 05:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Nuvalent stock logo

Nuvalent NASDAQ:NUVL

$82.07 +0.57 (+0.70%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$83.48 +1.41 (+1.72%)
As of 07/10/2025 06:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Telix Pharmaceuticals stock logo

Telix Pharmaceuticals NASDAQ:TLX

$16.10 -0.82 (-4.85%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$16.10 0.00 (0.00%)
As of 07/10/2025 04:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.